Pancreatic CancerPhase 2NCT00003591
Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer
A Phase 2 study testing paclitaxel and radiation therapy in people with Pancreatic Cancer, run by Radiation Therapy Oncology Group at 234 sites in 2 countries.
Trial summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer
- What is being tested?
- paclitaxel and radiation therapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 122 participants
- Where
- 234 sitesin 2 countries
- Study dates
- Nov 1998to Oct 2005
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS: Histologically confirmed nonmetastatic, unresectable pancreatic adenocarcinoma No evidence of metastatic disease in the major viscera and no peritoneal seeding Residual disease after resection (R-1 or -2 micro- and macroscopic residual) eligible if measurable disease on the post operative CT or MRI scan Recurrent disease following radical surgery is eligible All malignant disease must be encompassable within a single irradiation field Must be a radiographically assessable disease CT with 5 mm cuts or spiral CT
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,800/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL Biliary system stented Renal: Creatinine less than 3.0 mg/dL OR Creatinine clearance at least 40 mL/min Other: If patients have biliary or gastroduodenal obstruction, they must have drainage prior to starting chemoradiation Oral intake of at least 1,500 calories per day No significant infection or other coexistent medical condition
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior paclitaxel At least 4 weeks since prior gemcitabine No other prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the planned field Surgery: See Disease Characteristics
Trial locations and contacts
234 sites in 2 countries.
234 sites in 2 countries
United States218 sites
Akron General Medical Center
Akron, Ohio, 44302
Akron City Hospital
Akron, Ohio, 44309
Cancer Center of Albany Medical Center
Albany, New York, 12208
Veterans Affairs Medical Center - Albany
Albany, New York, 12208
Saint Joseph Medical Center
Albuquerque, New Mexico, 87102
Providence Cancer Therapy Center
Anchorage, Alaska, 99508
St. John's Medical Center
Anderson, Indiana, 46016
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
Anne Arundel Oncology Center
Annapolis, Maryland, 21401
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, 21201
Greater Baltimore Medical Center and Cancer Center
Baltimore, Maryland, 21204
Harbor Hospital Center
Baltimore, Maryland, 21225
Radiation Oncology Affiliates of Maryland, P.A.
Baltimore, Maryland, 21237
Johns Hopkins Oncology Center
Baltimore, Maryland, 21287
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Julie and Ben Rogers Cancer Institute
Beaumont, Texas, 77701
CCOP - Southwestern Vermont Regional Cancer Center
Bennington, Vermont, 05201
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, 35233
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, 35294
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Joint Center for Radiation Therapy
Boston, Massachusetts, 02215
Medical Center at Bowling Green
Bowling Green, Kentucky, 42102
Bridgeport Hospital
Bridgeport, Connecticut, 06610
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
New York Methodist Hospital
Brooklyn, New York, 11215-3609
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
Martha Jefferson Hospital
Charlottesville, Virginia, 22901
Cancer Center, University of Virginia HSC
Charlottesville, Virginia, 22908
Northwestern Memorial Hospital
Chicago, Illinois, 60611
University of Chicago Cancer Research Center
Chicago, Illinois, 60637
Christ Hospital
Cincinnati, Ohio, 45219
Lykes Center for Radiation Therapy
Clearwater, Florida, 33757-0210
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210
Mount Diablo Medical Center
Concord, California, 94524-4110
Samaritan Regional Cancer Center
Corvallis, Oregon, 97339
Penn State Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Mercy Catholic Medical Center, Mercy Fitzgerald Divison
Darby, Pennsylvania, 19023
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
Halifax Medical Center
Daytona Beach, Florida, 32114
University of Colorado Cancer Center
Denver, Colorado, 80262
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Beckman Research Institute, City of Hope
Duarte, California, 91010
Wendt Regional Cancer Center of Finley Hospital
Dubuque, Iowa, 52001
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07018-1095
John F. Kennedy Medical Center
Edison, New Jersey, 08818
Elizabeth General Medical Center - West
Elizabeth, New Jersey, 07201
Meritcare Roger Maris Cancer Center
Fargo, North Dakota, 58122
Hurley Medical Center
Flint, Michigan, 48503
Radiation Therapy Associates - Fort Myers
Fort Myers, Florida, 33901
California Cancer Center
Fresno, California, 93720
Saint Agnes Cancer Center
Fresno, California, 93720
University of Florida Health Science Center
Gainesville, Florida, 32610-0296
University of Texas Medical Branch
Galveston, Texas, 77555-1329
Glendale Memorial Hospital and Health Center
Glendale, California, 91204
St. Vincent Hospital
Green Bay, Wisconsin, 54307-3508
Sutter Health Western Division Cancer Research Group
Greenbrae, California, 94904
East Carolina University School of Medicine
Greenville, North Carolina, 27858-4354
CCOP - Greenville
Greenville, South Carolina, 29615
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Penn State Geisinger Cancer Center
Hershey, Pennsylvania, 17033
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030
Huntsville Hospital System
Huntsville, Alabama, 35801
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Clarion Health Partners Inc.
Indianapolis, Indiana, 46206-1367
Community Hospitals of Indianapolis - Regional Cancer Center
Indianapolis, Indiana, 46219
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
Jackson-Madison County General Hospital
Jackson, Tennessee, 38301
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
CCOP - Kansas City
Kansas City, Missouri, 64131
CCOP - Dayton
Kettering, Ohio, 45429
Baptist Regional Cancer Center - Knoxville
Knoxville, Tennessee, 37901
Gundersen Lutheran Medical Foundation
La Crosse, Wisconsin, 54601
Wilford Hall - 59th Medical Wing
Lackland Air Force Base, Texas, 78236-5300
Romagosa Radiation Oncology Center
Lafayette, Louisiana, 70501
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
Loma Linda University Medical Center
Loma Linda, California, 92354
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
Kaiser Permanente Medical Center - Los Angeles
Los Angeles, California, 90027
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033-0800
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
James Graham Brown Cancer Center
Louisville, Kentucky, 40202
Louisville Radiation Oncology
Louisville, Kentucky, 40215
Virginia Baptist Hospital
Lynchburg, Virginia, 24503
Veterans Affairs Medical Center - Madison
Madison, Wisconsin, 53705
Southern Wisconsin Radiotherapy Center
Madison, Wisconsin, 53713
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
Merle M. Mahr Cancer Center
Madisonville, Kentucky, 42431
Elliot Regional Cancer Center
Manchester, New Hampshire, 03103
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Marquette General Hospital
Marquette, Michigan, 49855
Marshfield Clinic
Marshfield, Wisconsin, 54449
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
Loyola University Medical Center
Maywood, Illinois, 60153
Health First Holmes Regional Medical Center
Melbourne, Florida, 32901
CCOP - Baptist Cancer Institute
Memphis, Tennessee, 38117
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee, 38163
Community Memorial Hospital
Menomonee Falls, Wisconsin, 53051
East Jefferson General Hospital
Metairie, Louisiana, 70011
Sylvester Cancer Center, University of Miami
Miami, Florida, 33136
Baptist Hospital of Miami
Miami, Florida, 33176-2197
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
South Jersey Hospital - Millville
Millville, New Jersey, 08332
St. Joseph's Hospital
Milwaukee, Wisconsin, 53210
Columbia Hospital
Milwaukee, Wisconsin, 53211
St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
UNI-MED Medical Center
Minot, North Dakota, 58701
Urology Associates - Mobile AL
Mobile, Alabama, 36640
MBCCOP - University of South Alabama
Mobile, Alabama, 36688
Alabama Oncology, LLC
Montgomery, Alabama, 36106-2801
Fox Chase Cancer Center at Virtua-Memorial Hospital Burlington County
Mount Holly, New Jersey, 08060
Ball Memorial Hospital
Muncie, Indiana, 47303-3499
Vanderbilt Cancer Center
Nashville, Tennessee, 37232-6838
MBCCOP - LSU Medical Center
New Orleans, Louisiana, 70112
CCOP - Ochsner
New Orleans, Louisiana, 70121
Kaplan Cancer Center
New York, New York, 10016
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
Whittingham Cancer Center
Norwalk, Connecticut, 06856
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
Methodist Cancer Center - Omaha
Omaha, Nebraska, 68114
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68131
Florida Radiation Oncology Group
Orange Park, Florida, 32073
MD Anderson Cancer Center Orlando
Orlando, Florida, 32806
Western Baptist Hospital
Paducah, Kentucky, 42001
Gulf Coast Cancer Treatment Center
Panama City, Florida, 32405-4587
Lutheran General Cancer Care Center
Park Ridge, Illinois, 60068
Bayshore Medical Center
Pasadena, Texas, 77504
West Florida Cancer Institute - Pensacola
Pensacola, Florida, 32514
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Allegheny University Hospitals- Hahnemann
Philadelphia, Pennsylvania, 19102-1192
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104
Veterans Affairs Medical Center - Philadelphia
Philadelphia, Pennsylvania, 19104
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, 19141
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224
Champlain Valley Physicians Hospital Medical Center
Plattsburgh, New York, 12901
Cancer Care Center
Pomona, California, 91767
Maine Medical Center
Portland, Maine, 04102
CCOP - Columbia River Program
Portland, Oregon, 97213
Naval Medical Center, Portsmouth
Portsmouth, Virginia, 23708-2197
Vassar Brothers Hospital
Poughkeepsie, New York, 12601
Lifespan: The Miriam Hospital
Providence, Rhode Island, 02906
Roger Williams Medical Center/Brown University
Providence, Rhode Island, 02908-4735
Southeastern Wisconsin Regional Cancer Center
Racine, Wisconsin, 53405
Reading Hospital and Medical Center
Reading, Pennsylvania, 19612-6052
Mercy Medical Center - Redding
Redding, California, 96099-6009
Massey Cancer Center
Richmond, Virginia, 23298-0037
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Genesee Hospital - Rochester
Rochester, New York, 14607
University of Rochester Cancer Center
Rochester, New York, 14642
InterCommunity Cancer Center at Rome
Rome, Georgia, 30161
Green Mountain Oncology Group
Rutland, Vermont, 05701
Radiation Oncology Center - Sacramento
Sacramento, California, 95816
St. Mary's Medical Center
Saginaw, Michigan, 48601
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
LDS Hospital
Salt Lake City, Utah, 84143
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94115-0128
Santa Cruz Radiation Oncology Medical Group, Inc.
Santa Cruz, California, 95065
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
Mercy Hospital Cancer Center - Scranton
Scranton, Pennsylvania, 18501
Swedish Hospital Tumor Institute
Seattle, Washington, 98104
Virginia Mason Medical Center
Seattle, Washington, 98111
Grand View Hospital
Sellersville, Pennsylvania, 18960
Memorial Hospital of South Bend
South Bend, Indiana, 46601
St. Joseph's Radiation Oncology Center
South Bend, Indiana, 46617
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Deaconess Medical Center
Spokane, Washington, 99210-0248
CCOP - Central Illinois
Springfield, Illinois, 62526
Cancer Research for the Ozarks
Springfield, Missouri, 65807
CCOP - Ozarks Regional
Springfield, Missouri, 65807
Veterans Affairs Medical Center - Saint Louis
St Louis, Missouri, 63106
St. Louis University Health Sciences Center
St Louis, Missouri, 63110-0250
Mallinckrodt Institute of Radiology
St Louis, Missouri, 63110
Dixie Regional Medical Center
St. George, Utah, 84770
Bayfront Medical Center
St. Petersburg, Florida, 33701
Stanford University
Stanford, California, 94305
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612
Albert Einstein Comprehensive Cancer Center
The Bronx, New York, 10461
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456
Community Medical Center
Toms River, New Jersey, 08755
David Grant Medical Center
Travis Air Force Base, California, 94535
St. Francis Medical Center
Trenton, New Jersey, 08629
Arizona Cancer Center
Tucson, Arizona, 85724
St. John Medical Center
Tulsa, Oklahoma, 74104
Radiation Oncology Associates of West Alabama
Tuscallosa, Alabama, 35401
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
South Georgia Medical Center
Valdosta, Georgia, 31603
New York Medical College
Valhalla, New York, 10595
Radiation Oncology Center - Walnut Creek
Walnut Creek, California, 94598
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
Schiffler Oncology Center
Wheeling, West Virginia, 26003
Veterans Affairs Medical Center - White River Junction
White River Junction, Vermont, 05009
Wilkes Barre General Hospital
Wilkes-Barre, Pennsylvania, 18764
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, 27157-1082
CCOP - MainLine Health
Wynnewood, Pennsylvania, 19096
Yakima Valley Memorial Hospital
Yakima, Washington, 98902
York Hospital
York, Pennsylvania, 17315
Canada16 sites
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Northeastern Ontario Regional Cancer Centre, Sudbury
Greater Sudbury, Ontario, P3E 5J1
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
Cancer Care Ontario-Hamilton Regional Cancer Centre
Hamilton, Ontario, L8V 5C2
Kingston Regional Cancer Centre
Kingston, Ontario, K7L 5P9
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6
Doctor Leon Richard Oncology Centre
Moncton, New Brunswick, E1C 8X3
McGill University Department of Oncology
Montreal, Quebec, H2W 1S6
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2W-W1T8
Ottawa Regional Cancer Centre - Civic Campus
Ottawa, Ontario, K1Y 4K7
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Northwestern Ontario Regional Cancer Centre, Thunder Bay
Thunder Bay, Ontario, P7A 7T1
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
British Columbia Cancer Agency - Vancouver Island Cancer Centre
Victoria, British Columbia, V8R 1J8
About this study
Official title: A Phase II Trial of External Irradiation (50.4 GY) and Weekly Paclitaxel (Taxol) for Non-Metastatic, Unresectable Pancreatic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients who have nonmetastatic, unresectable pancreatic cancer.
Read the detailed description
OBJECTIVES: I. Determine the response rate of patients with nonmetastatic, unresectable pancreatic cancer receiving external beam irradiation and weekly paclitaxel. II. Determine the median survival after this treatment in these patients. III. Evaluate the acute and late treatment morbidity of paclitaxel in these patients. IV. Correlate p53 status with treatment response to this treatment in this patient population.
OUTLINE: This is a open label, multicenter study. Patients are highly recommended to undergo laparoscopic surgical staging prior to protocol to exclude peritoneal and hepatic metastases. Patients receive paclitaxel IV over 3 hours weekly for 6 weeks beginning on day 1 followed 1.5 hours later by external beam radiotherapy daily 5 days a week for 5.5 weeks beginning on day 1. All patients are restaged with an abdominal CT scan 6 weeks following completion of chemoradiotherapy. If there is marked response to treatment at this time, curative surgery may be attempted at the discretion of the attending surgeon. Patients are followed every 3 months for 1 year, every 4 months for the second year, every 6 months for years 3-5, and annually thereafter.
PROJECTED ACCRUAL: A total of 100 patients will be accrued into this study over 12 months.
- Conditions
- Pancreatic Cancer
- Being tested
- paclitaxel, radiation therapy
- Keywords
- stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, recurrent pancreatic cancer, adenocarcinoma of the pancreas
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
paclitaxelDrug
radiation therapyRadiation
| Study group | Role | What they receive |
|---|---|---|
| Pacilitaxel + External Beam Radiation Therapy (PXRT) | Experimental | Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks. Receives: Drug: paclitaxel; Radiation: radiation therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine the one-year and median survival rates after PXRT
To determine the one-year and median survival rates after paclitaxel and external beam radiation therapy (PXRT)
Secondary outcomes (3)
To determine the response rate of PXRT in unresectable pancreatic cancer in a multi-center trial
To evaluate the acute and late treatment morbidity of paclitaxel in a multi-institutional setting
To correlate p53 status with treatment response to PXRT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Sep 2004 (estimated)
- Study startNov 1998
- Primary completionJun 2001
- Study completionOct 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 122 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radiation Therapy Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Tyvin A. Rich, MD, Study chair, University of Virginia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00003591
- Sponsor's protocol ID
- RTOG-9812
- Other IDs
- CDR0000066661
- Status last verified
- Nov 2013
- First submitted
- 1 Nov 1999
- Last updated
- 13 Nov 2013
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Garofalo MC, Winter K, Regine WF, et al.: Recursive partitioning analysis (RPA) of prognostic factors in six Radiation Therapy Oncology Group (RTOG) trials of chemoradiotherapy for unresectable pancreatic cancer. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-144, S80-1, 2006.
Konski AA, Winter K, Khor L, et al.: Over-expression of RIa subunit (RIas) of protein kinase A may be a marker for favorable pancreatic cancer: an analysis of patients treated on Radiation Therapy Oncology Group (RTOG) 98-12. [Abstract] American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January 2006, San Francisco, California. A-148, 2006.
Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol. 2004 Feb;27(1):51-6. doi: 10.1097/01.coc.0000046300.88847.bf.
PubMed 14758134Rich T, Harris J, Abrams R, et al.: A phase II study of external irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: a preliminary report of RTOG protocol 98-12. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-51, 29-30, 2001.
Study at a glance
From the registry record, last updated by the sponsor on 13 Nov 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Trial of External Irradiation (50.4 GY) and Weekly Paclitaxel (Taxol) for Non-Metastatic, Unresectable Pancreatic Cancer
- ClinicalTrials.gov ID
- NCT00003591
- Acronym / sponsor ID
- RTOG-9812
- Conditions
- Pancreatic Cancer
- Keywords
- stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, recurrent pancreatic cancer, adenocarcinoma of the pancreas
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 122 participants (actual)
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Nov 1998
- Primary completion
- Jun 2001 (actual)
- Study completion
- Oct 2005 (actual)
- First posted
- 13 Sep 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients who have nonmetastatic, unresectable pancreatic cancer.
Detailed description
OBJECTIVES: I. Determine the response rate of patients with nonmetastatic, unresectable pancreatic cancer receiving external beam irradiation and weekly paclitaxel. II. Determine the median survival after this treatment in these patients. III. Evaluate the acute and late treatment morbidity of paclitaxel in these patients. IV. Correlate p53 status with treatment response to this treatment in this patient population.
OUTLINE: This is a open label, multicenter study. Patients are highly recommended to undergo laparoscopic surgical staging prior to protocol to exclude peritoneal and hepatic metastases. Patients receive paclitaxel IV over 3 hours weekly for 6 weeks beginning on day 1 followed 1.5 hours later by external beam radiotherapy daily 5 days a week for 5.5 weeks beginning on day 1. All patients are restaged with an abdominal CT scan 6 weeks following completion of chemoradiotherapy. If there is marked response to treatment at this time, curative surgery may be attempted at the discretion of the attending surgeon. Patients are followed every 3 months for 1 year, every 4 months for the second year, every 6 months for years 3-5, and annually thereafter.
PROJECTED ACCRUAL: A total of 100 patients will be accrued into this study over 12 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pacilitaxel + External Beam Radiation Therapy (PXRT) | Experimental | Drug: paclitaxel, Radiation: radiation therapyPaclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| paclitaxel | Drug | Pacilitaxel + External Beam Radiation Therapy (PXRT) |
| radiation therapy | Radiation | Pacilitaxel + External Beam Radiation Therapy (PXRT) |
Primary outcome
To determine the one-year and median survival rates after PXRT
To determine the one-year and median survival rates after paclitaxel and external beam radiation therapy (PXRT)
3 secondary outcomes
To determine the response rate of PXRT in unresectable pancreatic cancer in a multi-center trial
To evaluate the acute and late treatment morbidity of paclitaxel in a multi-institutional setting
To correlate p53 status with treatment response to PXRT
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Nov 2013.
- BackgroundGarofalo MC, Winter K, Regine WF, et al.: Recursive partitioning analysis (RPA) of prognostic factors in six Radiation Therapy Oncology Group (RTOG) trials of chemoradiotherapy for unresectable pancreatic cancer. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-144, S80-1, 2006.
- Results publicationKonski AA, Winter K, Khor L, et al.: Over-expression of RIa subunit (RIas) of protein kinase A may be a marker for favorable pancreatic cancer: an analysis of patients treated on Radiation Therapy Oncology Group (RTOG) 98-12. [Abstract] American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January 2006, San Francisco, California. A-148, 2006.
- Results publication: PubMed 14758134Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol. 2004 Feb;27(1):51-6. doi: 10.1097/01.coc.0000046300.88847.bf.
- Results publicationRich T, Harris J, Abrams R, et al.: A phase II study of external irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: a preliminary report of RTOG protocol 98-12. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-51, 29-30, 2001.
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tyvin A. Rich, MD study chair
University of Virginia
234 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing paclitaxel and radiation therapy in people with Pancreatic Cancer, run by Radiation Therapy Oncology Group at 234 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 234 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine the one-year and median survival rates after PXRT. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00003591, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Nov 2013.